The Global Prostate
Cancer Therapeutics Market, by drug type (Hormonal Therapy, Anti-androgens,
Immunotherapy, Targeted Therapy, and Chemotherapy) and by distribution channel
(Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) was valued at
US$ 8,738.2 million in 2017 and is projected to exhibit a CAGR of 7.4% over the
forecast period (2017–2025).
Prostate cancer is a serious
health issue among men and has a large socioeconomic impact on the society. In
2017, the American Cancer Society estimated around 161,360 new diagnoses of
prostate cancer in the U.S., leading to 26,730 fatalities. The most common
sites for prostate cancer to metastasize are the seminal vesicles, the lymph
nodes, the lungs, and various bones around the hips and the pelvic region. The
various treatment for these new tumor is expected to create highly lucrative
growth scenario for the prostate cancer therapeutics market.
Furthermore, research,
development and approval of new therapies by companies is also contributing to
the growth of prostate cancer therapeutics. For instance, Eligard developed by
Tolmar Pharmaceuticals, Inc. is marketed in the U.S., Australia, and New
Zealand by Tolmar, and by the following partners in the remaining territories:
Astellas (Europe, Asia, and MENA), Sanofi (Canada), Key Oncologics (South
Africa) and HanAll (South Korea) for the palliative treatment of advanced
prostate cancer. These key developments in the prostate cancer therapeutics
enable to change the market dynamics over a given period of forecast for
efficient treatment.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1257
Browse 29 Market Data Tables and
33 Figures spread through 160 Pages and in-depth TOC on "Prostate Cancer
Therapeutics Market, by Drug Type (Hormonal Therapy, Anti-androgens,
Immunotherapy, Targeted Therapy, and Chemotherapy) and By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - Global
Forecast to 2025".
The complexity of the treatment
of prostate cancer at different stages has influenced the medical industry to
establish clinical evidences for novel therapies and significantly increase
their influence to capture the untapped potential of prostate cancer
therapeutics market, functioning as a key development opportunity that will propel
the market growth. Presently, Sipuleucel-T, brand name Provenge (made by
Dendreon Corporation) is an immune cell based vaccine, the only vaccine
available which has resulted in increased overall survival in
hormone-refractory prostate cancer patients. Increase in the prevalence of
prostate cancer and robust development of biosimilars by manufacturers to
ensure affordable treatment to the patients is also a major factor to drive
growth of the prostate cancer therapeutics market.
As per data published by the
World Cancer Research Fund International, over 1.1 million cases of prostate
cancer were reported worldwide in 2012, which accounts for around 8% of the
total tumor cases. Approvals of Zytiga and Xtandi in 2013 and 2014,
respectively, for the first-line treatment of metastatic castration-resistant
prostate cancer patients in Europe and the U.S., and for the treatment of
docetaxel-resistant patients in Japan, has contributed to the increase in sales
of both products. However, many of the drugs indicated for use in
non-metastatic patients, or prescribed in combination with already-costly
therapies in metastatic castration-resistant patients, are unaffordable for
patients in emerging economies and also in developed economies (for uninsured
patients). High cost of therapy hinders the preference for biologics, deterring
the market growth in terms of revenue.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/prostate-cancer-therapeutics-market-1257
In Canada, Prostate Cancer
Foundation of Canada supports research, cure, and prevention of prostate cancer
through an online portal. This portal provides detailed information regarding
symptoms, diagnosis, and commercially available treatment options. Such portals
offer free access of the services from prostate cancer support groups through
monthly peer meetings, special educational events, community health fairs and
more to people all around the world, which is resulting in growth of the prostate
cancer therapeutics market.
Key takeaways of the Prostate
Cancer Therapeutics Market:
The global prostate cancer
therapeutics market is expected to expand at a CAGR of 7.4% during the forecast
period (2017–2025) as there exists a largely untapped and highly lucrative
market especially in Asia Pacific, Latin America, Middle East and Africa.
Hormone Therapy is widely
preferred, as it helps to shrink the prostate and any cancer that has spread,
and makes the treatment more effective
Hospital Pharmacies is the major
distribution channel of prostate cancer therapeutics that drives the growth
owing to it being the primary care center for prostate cancer
Some of the major players
involved in global prostate cancer therapeutics market are Johnson &
Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc.,
Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Pharmaceuticals
Inc, Endo Pharmaceuticals, AbbVie, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1257
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment